Your browser doesn't support javascript.
loading
Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results.
Youssef, Eriene A; Berry-Kravis, Elizabeth; Czech, Christian; Hagerman, Randi J; Hessl, David; Wong, Chin Y; Rabbia, Michael; Deptula, Dennis; John, Amy; Kinch, Russell; Drewitt, Philip; Lindemann, Lothar; Marcinowski, Moritz; Langland, Rachel; Horn, Carsten; Fontoura, Paulo; Santarelli, Luca; Quiroz, Jorge A.
Afiliação
  • Youssef EA; Roche Pharmaceutical Research and Early Development, Neuroscience, Ophthalmology, and Rare Diseases, Roche Innovation Center New York, New York, NY, USA.
  • Berry-Kravis E; Departments of Pediatrics, Neurological Sciences, and Biochemistry, Rush University Medical Center, Chicago, IL, USA.
  • Czech C; Roche Pharmaceutical Research and Early Development, Neuroscience, Ophthalmology, and Rare Diseases, Roche Innovation Center Basel, Basel, Switzerland.
  • Hagerman RJ; Medical Investigation of Neurodevelopmental Disorders (MIND) Institute and Department of Pediatrics, University of California Davis, School of Medicine, Sacramento, CA, USA.
  • Hessl D; Medical Investigation of Neurodevelopmental Disorders (MIND) Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis, School of Medicine, Sacramento, CA, USA.
  • Wong CY; Genentech Research and Early Development, South San Francisco, CA, USA.
  • Rabbia M; Roche Product Development, Roche Innovation Center New York, New York, NY, USA.
  • Deptula D; ImmunoBrain Check Ltd., Ness-Ziona, Israel.
  • John A; Gilead Sciences, Foster City, CA, USA.
  • Kinch R; Eisai EMEA, Hatfield, UK.
  • Drewitt P; Roche Pharmaceutical Research and Early Development, Neuroscience, Ophthalmology, and Rare Diseases, Roche Innovation Center Welwyn, Welwyn, UK.
  • Lindemann L; Roche Pharmaceutical Research and Early Development, Neuroscience, Ophthalmology, and Rare Diseases, Roche Innovation Center Basel, Basel, Switzerland.
  • Marcinowski M; Roche Diagnostics GmbH, Mannheim, Germany.
  • Langland R; Genomics & Oncology Research, Roche Molecular Systems, Inc., Pleasanton, CA, USA.
  • Horn C; Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.
  • Fontoura P; Roche Neuroscience Product Development, Basel, Switzerland.
  • Santarelli L; Therachon, AG, Basel, Switzerland.
  • Quiroz JA; Solid Biosciences, Cambridge, MA, USA.
Neuropsychopharmacology ; 43(3): 503-512, 2018 02.
Article em En | MEDLINE | ID: mdl-28816242
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psicotrópicos / Piridinas / Antagonistas de Aminoácidos Excitatórios / Receptor de Glutamato Metabotrópico 5 / Síndrome do Cromossomo X Frágil / Imidazóis Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psicotrópicos / Piridinas / Antagonistas de Aminoácidos Excitatórios / Receptor de Glutamato Metabotrópico 5 / Síndrome do Cromossomo X Frágil / Imidazóis Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article